Literature DB >> 26142494

Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype.

Stefania Merighi1, Pier Andrea Borea1, Stefania Gessi2.   

Abstract

Over the last two decades, diabetes mellitus has become one of the most challenging health problems worldwide. Diabetes mellitus, classified as type I and II, is a pathology concerning blood glucose level in the body. The nucleoside adenosine has long been known to affect insulin secretion, glucose homeostasis and lipid metabolism, through activation of four G protein coupled adenosine receptors (ARs), named A1, A2A, A2B and A3. Currently, the novel promising subtype to develop new drugs for diabetes treatment is the A2BAR subtype. The use of selective agonists and antagonists for A2BAR subtype in various diabetic animal models allowed us to identify several effects of A2BAR signaling in cell metabolism. In particular, the focus of this review is to summarize the studies on purinergic signaling associated with diabetes through A2BARs modulation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenosine receptors; Diabetes; Inflammation; Therapeutic target

Mesh:

Substances:

Year:  2015        PMID: 26142494     DOI: 10.1016/j.phrs.2015.06.015

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

3.  Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.

Authors:  Claire Shepherd; Sean Robinson; Alice Berizzi; Laura E J Thompson; Louise Bird; Simone Culurgioni; Simon Varzandeh; Philip B Rawlins; Reid H J Olsen; Iva Hopkins Navratilova
Journal:  ACS Med Chem Lett       Date:  2022-06-06       Impact factor: 4.632

Review 4.  The purinergic signalling and inflammation in the pathogenesis and progression of diabetes: key factors and therapeutic targets.

Authors:  André Campos de Lima; Lucas Macedo Chaves; Samantha Nuncio Prestes; Aline Mânica; Andreia Machado Cardoso
Journal:  Inflamm Res       Date:  2022-06-01       Impact factor: 6.986

Review 5.  Purinergic signaling in diabetes and metabolism.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2020-12-25       Impact factor: 5.858

Review 6.  Adenosine A2B Receptor: From Cell Biology to Human Diseases.

Authors:  Ying Sun; Pingbo Huang
Journal:  Front Chem       Date:  2016-08-24       Impact factor: 5.221

Review 7.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

8.  Deficient Insulin-mediated Upregulation of the Equilibrative Nucleoside Transporter 2 Contributes to Chronically Increased Adenosine in Diabetic Glomerulopathy.

Authors:  Sebastián Alarcón; Wallys Garrido; Génesis Vega; Claudio Cappelli; Raibel Suárez; Carlos Oyarzún; Claudia Quezada; Rody San Martín
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 9.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

10.  Correlation of A2bAR and KLF4/KLF15 with Obesity-Dyslipidemia Induced Inflammation in Uygur Population.

Authors:  Cuizhe Wang; Xiaodan Ha; Wei Li; Peng Xu; Yajuan Gu; Tingting Wang; Yan Wang; Jianxin Xie; Jun Zhang
Journal:  Mediators Inflamm       Date:  2016-04-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.